# Data Sources

BioQuery integrates eight major cancer genomics databases, all accessible through natural language queries.

import { Callout } from 'nextra/components'

## Overview

| Source | Description | Samples | Data Types |
|--------|-------------|---------|------------|
| **TCGA** | The Cancer Genome Atlas | 11,000+ | Expression, Mutations, CNV, Survival |
| **TARGET** | Pediatric cancers | 6,000+ | Expression, Mutations, Clinical |
| **GTEx** | Normal tissue reference | 17,000+ | Expression |
| **CCLE** | Cancer cell lines | ~1,000 | Expression, Mutations |
| **CPTAC** | Proteomics | ~1,500 | Protein abundance |
| **GENIE** | Real-world clinical | 40,000+ | Clinical data |
| **iAtlas ICI** | Immunotherapy response | 2,142 | Immune features, Response, Survival |
| **GDSC** | Drug sensitivity | 978 cell lines | IC50, AUC, Drug response |

All data is accessed via [ISB-CGC BigQuery](https://bq-search.isb-cgc.org/) and BioQuery BigQuery for fast, reproducible queries.

---

## TCGA (The Cancer Genome Atlas)

The primary data source for adult cancer genomics.

### Available Cancer Types (33 types)

| Code | Cancer Type | Samples |
|------|-------------|---------|
| BRCA | Breast invasive carcinoma | ~1,100 |
| LUAD | Lung adenocarcinoma | ~600 |
| LUSC | Lung squamous cell carcinoma | ~500 |
| KIRC | Kidney renal clear cell carcinoma | ~530 |
| KIRP | Kidney renal papillary cell carcinoma | ~290 |
| GBM | Glioblastoma multiforme | ~170 |
| OV | Ovarian serous cystadenocarcinoma | ~300 |
| COAD | Colon adenocarcinoma | ~450 |
| STAD | Stomach adenocarcinoma | ~400 |
| PRAD | Prostate adenocarcinoma | ~500 |
| LIHC | Liver hepatocellular carcinoma | ~370 |
| PAAD | Pancreatic adenocarcinoma | ~180 |
| SKCM | Skin cutaneous melanoma | ~470 |
| HNSC | Head and neck squamous cell carcinoma | ~520 |
| BLCA | Bladder urothelial carcinoma | ~400 |
| THCA | Thyroid carcinoma | ~500 |
| UCEC | Uterine corpus endometrial carcinoma | ~550 |

[View all 33 cancer types](https://www.cancer.gov/ccg/research/genome-sequencing/tcga)

### Data Types

- **RNA-seq expression**: TPM-normalized, hg38 aligned
- **Somatic mutations**: MC3 mutation calls
- **Clinical/survival**: Overall survival, progression-free survival

### Example Queries

```
Is EGFR expression higher in LUAD vs LUSC?
What's the TP53 mutation rate in breast cancer?
Does high DDR1 predict worse survival in kidney cancer?
```

---

## TARGET (Therapeutically Applicable Research to Generate Effective Treatments)

Pediatric cancer genomics data.

### Available Cancer Types

| Code | Cancer Type | Samples |
|------|-------------|---------|
| ALL | Acute lymphoblastic leukemia | ~1,500 |
| AML | Acute myeloid leukemia | ~200 |
| NBL | Neuroblastoma | ~150 |
| OS | Osteosarcoma | ~100 |
| WT | Wilms tumor | ~120 |
| RT | Rhabdoid tumor | ~50 |
| CCSK | Clear cell sarcoma of kidney | ~20 |

### Common Synonyms

- "childhood leukemia" or "pediatric leukemia" → ALL
- "neuroblastoma" → NBL
- "Wilms tumor" or "nephroblastoma" → WT
- "osteosarcoma" or "bone cancer in children" → OS

### Example Queries

```
What is MYC expression in neuroblastoma?
Is MYCN amplified in neuroblastoma?
Compare TP53 in pediatric AML vs ALL
```

<Callout type="info">
  TARGET data uses the same RNA-seq pipeline as TCGA, so expression values are comparable.
</Callout>

---

## GTEx (Genotype-Tissue Expression)

Normal tissue expression reference for tumor vs normal comparisons.

### Available Tissues (54 tissues)

Common tissues used for comparison:

| Tissue | TCGA Comparison |
|--------|-----------------|
| Breast - Mammary Tissue | BRCA |
| Lung | LUAD, LUSC |
| Kidney - Cortex | KIRC, KIRP |
| Liver | LIHC |
| Colon - Transverse | COAD |
| Prostate | PRAD |
| Thyroid | THCA |
| Brain - Cortex | GBM, LGG |

### Example Queries

```
Is MYC upregulated in breast cancer compared to normal?
Compare DDR1 expression in lung cancer vs normal tissue
Is TP53 higher in tumors vs normal liver?
```

<Callout type="warning">
  GTEx samples are from healthy donors, while TCGA "matched normal" samples come from tissue adjacent to tumors. Results may differ.
</Callout>

---

## CCLE (Cancer Cell Line Encyclopedia)

Gene expression and mutation data for ~1,000 cancer cell lines.

### Available Primary Sites

| Site | Cell Lines |
|------|------------|
| Lung | 173 |
| Haematopoietic/lymphoid | 167 |
| Breast | 62 |
| Large intestine | 58 |
| Skin | 54 |
| Central nervous system | 46 |
| Ovary | 46 |
| Pancreas | 41 |
| Stomach | 37 |

### Data Types

- **Expression**: RMA-normalized microarray (Affymetrix)
- **Mutations**: Whole-exome sequencing

### Example Queries

```
What is DDR1 expression in lung cancer cell lines?
Which cell line sites have highest EGFR expression?
Is BRAF mutated in melanoma cell lines?
```

<Callout type="info">
  CCLE expression uses RMA normalization, not TPM. Values are not directly comparable to TCGA RNA-seq data.
</Callout>

---

## CPTAC (Clinical Proteomic Tumor Analysis Consortium)

Mass spectrometry-based proteomics data.

### Available Cancer Types

| Code | Cancer Type | Samples |
|------|-------------|---------|
| CCRCC | Clear cell renal cell carcinoma | ~110 |
| GBM | Glioblastoma | ~100 |
| HNSCC | Head and neck squamous cell carcinoma | ~110 |
| LSCC | Lung squamous cell carcinoma | ~110 |
| LUAD | Lung adenocarcinoma | ~110 |
| PDA | Pancreatic ductal adenocarcinoma | ~140 |
| UCEC | Uterine corpus endometrial carcinoma | ~100 |
| BRCA | Breast cancer | ~120 |
| COAD | Colon adenocarcinoma | ~110 |
| OV | Ovarian cancer | ~80 |

### Data Types

- **Protein abundance**: Log2 ratio vs pooled reference
- **Phosphoproteomics**: Phosphosite quantification (available for most cancer types)

### Example Queries

```
What is TP53 protein abundance in glioblastoma?
Compare DDR1 protein levels across CPTAC cancers
Does DDR1 mRNA correlate with protein in breast cancer?
```

<Callout type="warning">
  Protein abundance is reported as log2 ratios relative to a pooled reference, not absolute concentrations.
</Callout>

---

## GENIE (Genomics Evidence Neoplasia Information Exchange)

Real-world clinical genomics data from multiple cancer centers.

### Overview

- **Patients**: ~40,000+
- **Institutions**: DFCI, MSK, VICC, JHU, and others
- **Data**: Clinical characteristics, demographics

### Available Cancer Sites

| Site | Patients |
|------|----------|
| Lung | ~7,000 |
| Breast | ~5,000 |
| Colon | ~4,500 |
| CNS | ~2,700 |
| Skin | ~2,000 |
| Ovary | ~1,800 |
| Pancreas | ~1,600 |
| Prostate | ~1,500 |

### Example Queries

```
What is the age distribution in lung cancer patients?
Clinical summary for breast cancer patients
```

<Callout type="info">
  GENIE currently provides clinical/demographic data. Genomic data (mutations, expression) coming soon.
</Callout>

---

## iAtlas ICI (Immunotherapy Response Data)

Checkpoint inhibitor response data from 23 published clinical studies.

### Overview

- **Studies**: 23 published ICI trials
- **Samples**: 2,142 patients
- **ICI Targets**: PD-1, PD-L1, CTLA-4, combinations

### Available Studies (Selected)

| Study | Cancer | ICI Target | Samples |
|-------|--------|------------|---------|
| IMVigor210 | Bladder | PD-L1 | 348 |
| Anders 2022 | Breast | PD-1 | 345 |
| IMmotion150 | Kidney | PD-L1 | 263 |
| Liu 2019 | Melanoma | PD-1 | 122 |
| Gide 2019 | Melanoma | PD-1/CTLA-4 | 91 |
| PRINCE | Pancreas | PD-1 | 104 |

[Full study list available in documentation]

### Data Types

- **Response status**: Responder/Non-responder classification
- **Immune features**: TIDE score, MIRACLE score, immune cell fractions
- **Survival**: Overall survival, progression-free survival

### Example Queries

```
What predicts immunotherapy response in melanoma?
How does PD-L1 expression affect ICI response?
Survival analysis for ICI responders vs non-responders
```

<Callout type="info">
  Data sourced from [iAtlas](https://www.cri-iatlas.org/) - the Cancer Research Institute's immunotherapy data portal.
</Callout>

---

## GDSC (Genomics of Drug Sensitivity in Cancer)

Drug sensitivity data (IC50, AUC) across cancer cell lines.

### Overview

- **Measurements**: 575,000+ drug-cell line combinations
- **Drugs**: 542 compounds
- **Cell Lines**: 978 cancer cell lines
- **Cancer Types**: 32 tissue types

### Data Types

- **IC50**: Half maximal inhibitory concentration (µM)
- **AUC**: Area under dose-response curve
- **Drug targets**: Putative gene targets for each drug
- **Pathway annotations**: Drug mechanism pathways

### Example Queries

```
How sensitive are cells to Erlotinib?
What drugs target BRAF and how effective are they?
What is the IC50 of Imatinib in leukemia cell lines?
```

### Common Drug Classes

| Class | Example Drugs | Target |
|-------|---------------|--------|
| EGFR inhibitors | Erlotinib, Gefitinib | EGFR |
| BRAF inhibitors | Vemurafenib, Dabrafenib | BRAF |
| MEK inhibitors | Trametinib, Selumetinib | MEK1/2 |
| BCR-ABL inhibitors | Imatinib, Dasatinib | BCR-ABL |
| PI3K inhibitors | Pictilisib, Alpelisib | PIK3CA |

<Callout type="info">
  Data from [GDSC Release 8.5](https://www.cancerrxgene.org/) (October 2023) - the Genomics of Drug Sensitivity in Cancer project.
</Callout>

---

## Data Access

All BioQuery data is accessed via the [ISB-CGC BigQuery](https://bq-search.isb-cgc.org/) public datasets. This ensures:

- **Speed**: Sub-second query execution on terabytes of data
- **Reproducibility**: Exact SQL queries provided for every analysis
- **Transparency**: All tables and versions documented

### BigQuery Tables Used

```
# TCGA
isb-cgc-bq.TCGA.RNAseq_hg38_gdc_current
isb-cgc-bq.TCGA.masked_somatic_mutation_hg38_gdc_current
isb-cgc-bq.TCGA.clinical_gdc_current

# TARGET
isb-cgc-bq.TARGET.RNAseq_hg38_gdc_current
isb-cgc-bq.TARGET.masked_somatic_mutation_hg38_gdc_current

# GTEx
isb-cgc.GTEx_v7.gene_median_tpm

# CCLE
isb-cgc-bq.CCLE.RMA_expression_hg19_current
isb-cgc-bq.CCLE.somatic_mutation_hg19_current

# CPTAC
isb-cgc-bq.CPTAC.quant_proteome_*

# GENIE
isb-cgc-bq.GENIE.clinical_gdc_current

# iAtlas ICI (BioQuery BigQuery)
bioquery-frontend.iatlas_ici.samples
bioquery-frontend.iatlas_ici.immune_features

# GDSC (BioQuery BigQuery)
bioquery-frontend.gdsc.drug_response
```
